Preparing an MDR Clinical Evaluation Report is one of the most challenging but essential steps in demonstrating the safety and performance of a medical device under the EU Medical Device Regulation (MDR). The process requires manufacturers to integrate multiple regulatory guidances, MDCG 2020‑6, MDCG 2020‑5, MDCG 2020‑13, MEDDEV 2.7/1 rev.4, and MDR Annex XIV, into a single, structured, and evidence‑driven CER.
This article breaks down how these documents support a compliant MDR Clinical Evaluation Report and what manufacturers must focus on to meet Notified Body expectations.
Key MDR Clinical Evaluation Report Requirements in Annex XIV
Building a Strong Clinical Evaluation Plan (CEP)
Annex XIV requires manufacturers to create a Clinical Evaluation Plan outlining:
- Objectives and methodology
- Data sources
- Appraisal criteria
- Update frequency across the device lifecycle
The CEP must remain a living document that evolves with device changes, PMS findings, and state‑of‑the‑art updates.
Demonstrating Safety and Performance
Your MDR Clinical Evaluation Report must show that the device meets GSPRs based on methodologically sound, relevant, and sufficient clinical data. Evidence may include:
- Literature
- Clinical investigations
- PMS and PMCF data
- Real‑world evidence
Benefit–Risk Determination
The CER must contain a transparent benefit–risk assessment based on:
- Intended purpose
- Clinical outcomes
- Residual risks
- Available alternatives and state of the art
How MEDDEV 2.7/1 rev.4 Supports MDR Clinical Evaluation Reports
Although created for the MDD, MEDDEV 2.7/1 rev.4 still provides the methodological foundation used by notified bodies.
Stage‑Based Clinical Evaluation Framework
MEDDEV outlines a structured, reproducible approach that aligns well with MDR expectations:
- CEP creation
- Identification of clinical data
- Appraisal of data quality and scientific validity
- Analysis and risk‑benefit assessment
- CER production and ongoing updates
Its systematic approach remains essential for building an MDR‑compliant CER.
How MDCG 2020‑6 Supports Legacy Devices in the MDR CER
MDCG 2020‑6 explains how to demonstrate sufficient clinical evidence for legacy devices.
When Clinical Investigations Are Necessary
Additional clinical studies may be required if:
- Existing data is insufficient
- The device has undergone significant changes
- The device is high risk (e.g., implants, Class III)
PMCF as an Ongoing Requirement
Manufacturers must implement a PMCF plan to:
- Confirm continued safety and performance
- Collect real‑world evidence
- Update the CER regularly
MDCG 2020‑6 reinforces that legacy devices need a full reevaluation—not a simple MDD carryover.
Using MDCG 2020‑5 for Equivalence in the MDR Clinical Evaluation Report
MDCG 2020‑5 clarifies how to establish equivalence, which is critical if you plan to use clinical data from an existing device.
Three Required Equivalence Dimensions
To claim equivalence, manufacturers must show alignment in:
- Technical characteristics
- Biological characteristics
- Clinical characteristics
Robust documentation and legitimate access to clinical data from the equivalent device are mandatory.
Risk Considerations
Manufacturers must also show:
- Differences do not impact clinical safety or performance
- Risks are identified and mitigated
- Claims remain scientifically justified
How MDCG 2020‑13 Aligns CERs With Notified Body Review
MDCG 2020‑13 provides the Clinical Evaluation Assessment (CEA) report template used by Notified Bodies. Understanding this structure helps manufacturers prepare CERs that meet reviewer expectations.
Key Focus Areas for Notified Bodies
- Device description and intended purpose
- Definition of state of the art
- GSPR alignment
- CEP adequacy and methodology
- Data sources and appraisal quality
- Clinical evidence strength and conclusions
- PMCF requirements
Manufacturers who align their CER to this structure often experience smoother reviews and fewer NB questions.
Ensuring Regulatory Compliance in Your MDR Clinical Evaluation Report
To achieve a defensible, audit‑ready CER, manufacturers must integrate:
- MDR Annex XIV clinical evaluation requirements
- MEDDEV methodology and appraisal principles
- MDCG 2020‑6 for legacy device evidence
- MDCG 2020‑5 for equivalence justification
- MDCG 2020‑13 for NB review expectations
A compliant MDR Clinical Evaluation Report demonstrates:
- Scientific validity
- Clinical performance
- Clinical safety
- A documented, robust benefit–risk profile
How MDx CRO Supports Your MDR Clinical Evaluation Report
MDx CRO specializes in supporting manufacturers through the full MDR CER process. Our services include:
- Regulatory strategy and intended purpose definition
- Customized MDR Clinical Evaluation Report templates
- Clinical Evaluation Plan (CEP) development
- Systematic literature reviews
- CER and CEP medical writing
- Gap analyses for clinical evidence and QMS alignment
- Equivalence assessments
- PMCF plan development
- Technical documentation for MDR compliance
- Support with Notified Body interactions
Our experts ensure that your CER is complete, consistent, and aligned with the latest MDR and MDCG expectations.
